Real-World Early Treatment with Room Temperature–Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses

Treating hemophilia A or B patients with inhibitors is particularly challenging, as they do not respond to replacement therapy with factor VIII or factor IX concentrates. A room temperature–stable formulation of recombinant activated factor VII (rFVIIa; NovoSeven (®) ), which provides improved conve...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:TH Open
Main Authors: Demartis, Francesco, Batorova, Angelika, Chambost, Hervé, Eshghi, Peyman, Karimi, Mehran, Kavakli, Kaan, El Fegoun, Soraya Benchikh, Cepo, Katarina, Vestergaard, Lene Sommer, Benson, Gary
Formato: Artigo
Idioma:Inglês
Publicado em: Georg Thieme Verlag KG 2017
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6524848/
https://ncbi.nlm.nih.gov/pubmed/31249918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/s-0037-1608943
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados